The Utility of Eye Tracking‐Based Cognitive Assessment in Clinical Practice

ABSTRACT Backgraund MIREVO is a recently developed software that employs eye‐tracking‐based cognitive assessment (ETCA) for dementia screening and was approved for clinical use in Japan. However, evidence regarding its clinical utility is limited. Aim To evaluate the clinical utility of the ETCA application as a screening tool for dementia by examining score associations with established neuropsychological tests and diagnostic accuracy. Methods Ninety‐two patients attending a memory clinic were assessed using the ETCA app, Mini‐Mental State Examination (MMSE), and Revised Hasegawa Dementia Scale (HDS‐R). Correlations were analyzed using Spearman's rank correlation coefficient. Group differences were examined using analysis of variance. Diagnostic accuracy and optimal cutoff values were determined using receiver operating characteristic curves. Results Over 95% of the patients completed the ETCA, and the corresponding scores were significantly correlated with those of the MMSE ( r = 0.603) and HDS‐R ( r = 0.587). The ETCA scores differed significantly among groups with no cognitive impairment, mild cognitive impairment, and dementia. The ETCA exhibited good diagnostic accuracy for distinguishing dementia from non‐dementia (area under the curve = 0.830), comparable to the MMSE and HDS‐R scores. A cutoff value of 41.3 yielded a sensitivity of 75.0% and a specificity of 80.8%. Conclusion The ETCA application is a feasible and effective screening tool for dementia in routine clinical practice, exhibiting a diagnostic performance comparable to that of conventional cognitive tests. However, ETCA scores should be interpreted with caution in very old adults, who may exhibit lower scores than on traditional scales.